Dr. Nathenson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
# Dana-Far
Boston, MA 02215Phone+1 617-582-9396- Is this information wrong?
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2015 - 2016
University of MarylandFellowship, Hematology and Medical Oncology, 2012 - 2015
UPMC Medical EducationResidency, Internal Medicine, 2009 - 2012
Tufts University School of MedicineClass of 2009
Certifications & Licensure
MA State Medical License 2016 - 2025
NH State Medical License 2024 - 2024
RI State Medical License 2020 - 2020
TX State Medical License 2015 - 2017
MD State Medical License 2012 - 2015
PA State Medical License 2009 - 2012- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas Start of enrollment: 2019 May 13
Publications & Presentations
PubMed
- 55 citationsCharacteristics of mismatch repair deficiency in sarcomas.Leona A. Doyle, Jonathan A. Nowak, Michael J. Nathenson, Katherine Thornton, Andrew J. Wagner
Modern Pathology. 2019-02-14 - 1588 citationsEfficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and ChildrenAlexander Drilon, Theodore W. Laetsch, Shivaani Kummar, Steven G. DuBois, Ulrik Lassen
The New England Journal of Medicine. 2018-02-21 - 10 citationsGuillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptorJocelyn Joseph, Michael J. Nathenson, Van Anh Trinh, Karan Malik, Erica N. Nowell
Journal for Immunotherapy of Cancer. 2019-11-08
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
